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Essentials
• Russell’s viper envenoming is a major health issue in
South Asia and causes coagulopathy.
• We studied the effect of fresh frozen plasma and two
antivenom doses on correcting coagulopathy.
• Fresh frozen plasma did not hasten recovery of coagu-
lopathy.
• Low-dose antivenom did not worsen coagulopathy.
Summary. Background: Russell’s viper (Daboia russelii)
envenoming is a major health issue in South Asia and
causes venom-induced consumption coagulopathy
(VICC). Objectives: To investigate the effects of fresh
frozen plasma (FFP) and two antivenom doses in cor-
recting VICC. Methods: We undertook an open-label
randomized controlled trial in patients with VICC at
two Sri Lankan hospitals. Patients with suspected Russell’s
viper bites and coagulopathy were randomly allocated
(1 : 1) to high-dose antivenom (20 vials) or low-dose antive-
nom (10 vials) plus 4 U of FFP. The primary outcome was
the proportion of patients with an International Normalized
Ratio (INR) of < 2 at 6 h after antivenom administration.
Secondary outcomes included anaphylaxis, major hemor-
rhage, death, and clotting factor recovery. Results: From
214 eligible patients, 141 were randomized: 71 to high-dose
antivenom, and 70 to low-dose antivenom/FFP; five had no
post-antivenom blood tests. The groups were similar except
for a delay of 1 h in antivenom administration for FFP
patients. Six hours after antivenom administration, 23 of 69
(33%) patients allocated to high-dose antivenom had an
INR of < 2, as compared with 28 of 67 (42%) allocated to
low-dose antivenom/FFP (absolute difference 8%; 95%
confidence interval  8% to 25%). Fifteen patients allo-
cated to FFP did not receive it. Severe anaphylaxis occurred
equally frequently in each group. One patient given FFP
developed transfusion-related acute lung injury. Three
deaths occurred in low-dose antivenom/FFP patients,
including one intracranial hemorrhage. There was no differ-
ence in recovery rates of INR or fibrinogen, but there was
more rapid initial recovery of factor V and FX in FFP
patients. Conclusion: FFP after antivenom administration
in patients with Russell’s viper bites did not hasten recovery
of coagulopathy. Low-dose antivenom/FFP did not worsen
VICC, suggesting that low-dose antivenom is sufficient.
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Introduction
Snakebite continues to be a major health issue in the
rural tropics, particularly in resource-poor regions of
Asia, Africa, and Latin America. Although it is difficult
to estimate the numbers of envenoming cases and deaths
each year, these are in excess of half a million and tens of
thousands, respectively [1]. The major clinical syndromes
of snake envenoming are coagulopathy, neurotoxicity
(paralysis), myotoxicity, local cytotoxicity/necrosis, and
acute kidney injury. Venom-induced consumption coagu-
lopathy (VICC) is the most frequent serious complication,
and can result in major hemorrhage and death [2],
although the less common neurotoxicity carries a higher
risk of a fatal outcome [3]. Treatment includes antivenom
and, potentially, clotting factor replacement, but the evi-
dence to support their effectiveness in resolving VICC is
limited; there are no placebo-controlled trials of antive-
nom [4], and only one of fresh frozen plasma (FFP) [5].
The majority of studies of FFP in VICC have been obser-
vational in nature [6–9].
Russell’s viper (Dabaoi russelii) is a snake of major
medical importance in South and Southeast Asia [10–12].
The major manifestation of envenoming is VICC, which
is characterized by decreased levels of fibrinogen, fac-
tor V, FVIII, and FX, leading to a prolonged prothrom-
bin time (PT: International Normalized Ratio [INR]) and
a prolonged activated partial thromboplastin time
(APTT) [13]. The procoagulant activity of the venom is
attributable to metalloproteinases, which are FX and FV
activators [14]. VICC is the most common indication for
antivenom administration in patients with Russell’s viper
bites, although there is ongoing controversy over the dose
of antivenom (initial dose of 10 or 20 vials), repeat anti-
venom dosing, and the use of factor replacement. We
have recently shown that recovery of coagulopathy occurs
over a period of 24–48 h in patients given 10 vials of anti-
venom [15]. Even so, full recovery of clotting function
takes up to 48 h, during which time the patient poten-
tially remains at risk of bleeding. Theoretically, FFP
administration should rapidly correct the coagulopathy
in the absence of ongoing venom-induced clotting
factor consumption. This has been shown for Australian
elapid snakebites, but has not been investigated in viper
envenoming.
There is also concern that a low dose of antivenom is
insufficient to neutralize all of the venom, and, followed
by the administration of FFP, could re-initiate the con-
sumption process, extending the duration of the coagu-
lopathy. In a study of FFP in Australian elapid
envenoming causing VICC, the administration of FFP
sped up the recovery of the coagulopathy, except when it
was given < 6 h after the bite [5]. However, the etiology
of VICC is different for Russell’s viper venom, which
contains metalloproteinase FX and FV activators, rather
than a serine protease prothrombin activator [16]. The
coagulopathy from the latter develops rapidly and
appears to resolve irrespective of antivenom [17], whereas
Russell’s viper VICC appears to be slower in onset, and
recovery is delayed unless antivenom is administered.
We hypothesized that FFP would hasten the recovery
of the coagulopathy in patients with Russell’s viper bite
after the administration of 10 vials of antivenom. We
compared this lower dose of antivenom plus FFP with
high-dose antivenom, to determine whether this resulted
in more or less rapid correction of clotting function in
patients bitten by Russell’s vipers.
Materials and methods
We undertook an open-label randomized controlled trial
comparing low-dose antivenom (10 vials) plus FFP (4U)
with high-dose antivenom (20 vials) without FFP at two
Sri Lankan hospitals in patients with VICC from Rus-
sell’s viper envenoming. The study was approved by the
Ethical Review Committee, University of Peradeniya, Sri
Lanka, and the Human Ethics Research Committee of
the University of Newcastle, Australia. All patients gave
written and informed consent. The study was registered
with the Sri Lankan Clinical Trials Registry (number
SLCTR/2010/011).
Study recruitment and patients
All patients (aged > 15 years) with a suspected snakebite
presenting to the Base Hospital Polonnaruwa from Octo-
ber 2012 to March 2015, or the Base Hospital Kurune-
gala from May 2013 to March 2015, were recruited to a
prospective cohort study. From all patients with sus-
pected snakebites, we aimed to recruit patients with VICC
to the randomized clinical trial. The inclusion criteria for
the randomized clinical trial were a suspected Russell’s
viper (D. russelii) bite with coagulopathy defined as an
abnormal 20-min whole blood clotting test (20WBCT).
Sufficient FFP also had to be available to administer
within 4 h of commencement of antivenom administra-
tion. Exclusion criteria were a definite bite by a another
snake, pregnancy, age < 16 years, allergy to blood
products, and prior antivenom administration (such as at
a primary hospital before transfer). Patients could
also be excluded by their treating physician if they were
not happy to give the doses of antivenom in the study,
or wanted to determine whether FFP was to be
administered.
Treatment protocol
All patients with snakebites underwent an initial assess-
ment by clinical research assistants, including collection
of baseline clinical data, symptoms and signs of snake
envenoming, 20WBCT, and information on snake identi-
fication. The study was explained to patients with a
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suspected Russell’s viper bite and a positive 20WBCT by
a clinical research assistant, in their native language (Sin-
hala, Tamil, or English). Written informed consent was
then obtained, and the patients were randomized in a
1 : 1 ratio to either low-dose antivenom (10 vials) plus
FFP, or high-dose antivenom (20 vials).
Block randomization was used for each of the two study
hospitals to maintain balance at both sites. Blocks of 2
and 4 (e.g. AB, BA or AABB, ABAB, etc.) were randomly
generated with Microsoft Excel, producing two separate
random sequences of allocations. The random allocation
was provided to clinical research assistants at each hospital
from a central contact (F.M.), so that the patient, treating
team, research assistants and investigators were all blinded
to allocation. All patients received Indian polyvalent anti-
venom from VINS Bioproducts (Hyderabad, India) over a
period of 1 h, with the low-dose antivenom group receiv-
ing 10 vials and the high-dose group receiving 20 vials.
Those patients allocated to low-dose antivenom and FFP
then received 4 U of FFP (approximately 1000 mL; 10–
15 mL kg1) over a period of 30–60 min. The treating
team cross-matched and ordered FFP, and either the
blood bank supplied FFP (daytime) or a senior house offi-
cer (night-time) obtained FFP from the blood bank.
Patients not allocated to FFP were not to receive FFP
until after the 6-h primary outcome. Any further antive-
nom administration was determined by the treating doctor
(s), but was discouraged prior to the 6-h primary outcome
time.
All patients had a 10-mL blood sample collected prior
to antivenom administration (baseline), and then a further
5 mL collected at 1, 3, 6, 12 and 24 h after antivenom
administration, and daily until discharge. Blood was col-
lected in serum and citrated tubes, immediately cen-
trifuged for 7 min at 3000 r.p.m., aliquoted, and frozen
at  20 °C for 1–2 weeks, before being transported in
mobile freezer units to a central location to be stored at
 80 °C until the completion of the study. All samples
were then sent to the Clinical Toxicology Research Group
Laboratory, University of Newcastle, Australia for analy-
sis. Thermocrons set to measure the temperature every
7 min were used to confirm that samples had not thawed.
Data collection
Demographic information (sex and age), details of the
bite, information on snake identification, clinical features
of snake envenoming, 20WBCT results, treatment (trial
treatment; repeat antivenom), adverse effects, complica-
tions (hemorrhage, acute kidney injury, and death) and
study outcomes were recorded on clinical research data-
sheets, which were then entered into a relational database
(Microsoft Access) by a single trained data entry research
assistant. Baseline observations were recorded prior to
antivenom administration. Blood pressure, heart rate, res-
piratory rate, oxygen saturation and any features of
systemic hypersensitivity reactions were then recorded.
Systemic hypersensitivity reactions were classified as ana-
phylaxis according to the National Institute of Allergy
and Infectious Disease/Food Allergy and Anaphylaxis
Network consensus criteria [18], and classified as severe
according to the Brown grading system [19].
Laboratory assays
A previously developed venom-specific enzyme
immunoassay was used to measure Russell’s viper venom
concentrations in serum samples [20,21]. Briefly, poly-
clonal IgG antibodies raised in rabbits against Russell’s
viper venom were bound to microplates and also conju-
gated with biotin as detecting antibodies for a sandwich
enzyme immunoassay. The detecting agent was strepta-
vidin–horseradish peroxidase. In cases where no pre-anti-
venom sample was available or venom was not detected,
a post-antivenom sample was subjected to dissociation
treatment so that any free venom could be measured with
the enzyme immunoassay [22].
PT, INR, APTT, D-dimer, FI (fibrinogen), FV, FVIII
and FX were measured in citrated plasma samples. All
assays were performed on a Sysmex CS-2000i automated
blood coagulation analyser (Sysmex Corporation, Chuo-
Ku, Kobe, Japan) with standard coagulometric or
immunoturbimetric methods according to the manufac-
turer’s protocols.
Data analysis
The primary outcome was the proportion of patients with
an INR of < 2 at 6 h post-antivenom administration. The
INR measured at the closest collection time before or after
6 h was used. Secondary outcomes included: (i) recurrence
of coagulopathy defined as an increase in INR of > 2 in
responding patients (INR of < 2 at 6 h); (ii) recurrence of
venom antigenemia, defined as an increase in the detection
of venom after an undetectable venom concentration [15];
(iii) anaphylaxis resulting from antivenom or FFP; (iv)
major hemorrhage as defined by the ISTH [23]; (v) transfu-
sion-related lung injury (TRALI); and (vi) death prior to
discharge. We also undertook an additional analysis that
was not predefined, in which we only included patients
who developed coagulopathy (INR of > 2, rather than a
positive 20WBCT) and had an INR measured between 4 h
and 9 h after antivenom administration.
In addition, the recovery of coagulopathy in the two
groups was compared by the use of survival analysis, with
the following events being used to measure recovery: time
to fibrinogen of > 1 g L1, INR of < 2, FV > 50%, and
FX > 50%. The areas under the curve (AUCs) of D-
dimer were compared to determine whether FFP caused
further consumption.
The sample size was based on a previous Australian
study [24], in which ~ 25% of patients not given FFP
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recovered to an INR of < 2 after 6 h. This was confirmed
in the recent controlled trial in Australia [5]. We assumed
that the process of recovery after antivenom administra-
tion and toxin neutralization was similar for different
snakes. An absolute increase of 25% of patients recover-
ing 6 h after antivenom administration was regarded as
clinically significant and sufficient to warrant the use of
FFP. In order to detect whether low-dose antivenom and
FFP increase the proportion of patients recovering at 6 h
from 25% to 50%, with a significance level (alpha) of 5%
and a power of 90%, a minimum of 85 patients were to
be recruited to each arm (i.e. a total of 170 patients). We
aimed to recruit 200 patients, to allow for missing out-
come data.
There was no planned interim analysis, but a Data
Monitoring Committee was established to review adverse
effects. If > 10% of patients developed severe adverse
effects attributed to FFP (anaphylaxis or TRALI), the
study was to be stopped. Unfortunately, the rates of
enrollment to the study decreased dramatically in the last
year, owing to the sudden decrease in cases of Russell’s
viper envenoming in both hospitals. In this region of Sri
Lanka, mechanical harvesting was introduced during the
study, resulting in fewer Russell’s viper bites. In addition,
there was increased antivenom use at referral hospitals,
reducing patient recruitment. The study was stopped after
randomization of 141 patients of the 200, because grant
funding had finished.
One author (K.M.), who remained blinded to treatment
allocation, extracted and de-identified the data from the
trial database before classifying the primary and sec-
ondary outcomes. The chief investigator (G.I.), also
blinded to treatment allocation, checked for missing or
inconsistent data, and then unblinded treatment alloca-
tions supplied by the research team (F.M.).
Statistical analysis
Medians and interquartile ranges (IQRs) were used for
continuous variables, and 95% confidence intervals (CIs)
were calculated for proportions. The primary outcome
was analyzed by intention to treat with Fisher’s exact test.
A per-protocol analysis and a non-randomized analysis of
treatment actually given were also undertaken. The latter
compared patients who received high-dose antivenom or
low-dose antivenom plus FFP within 6 h. Appropriate
statistical tests were used for the secondary outcomes,
based on whether the data were parametric or non-para-
metric. Time to recovery of clotting (INR of < 2) and
time to clotting factor recovery were analyzed with sur-
vival analysis and compared by use of the Gehan–Bres-
low–Wilcoxon test. Serial clotting time and clotting factor
data were also plotted and compared visually. For factors
for which there appeared to be a difference, a one-phase
association model was fitted to compare the half-times of
recovery. Statistical significance was taken as P < 0.05.
All statistical analyses were performed with GRAPHPAD
PRISM version 6.03 for Windows (GraphPad Software,
San Diego, CA, USA; www.graphpad.com).
Results
From 214 eligible patients identified during the study per-
iod, 141 consented and were randomized; 71 to high-dose
antivenom alone, and 70 to low-dose antivenom and FFP
(Fig. 1). Five patients did not have blood collected after
antivenom administration for the primary outcome, leav-
ing 136 for the analysis. The patients allocated to each
study arm had similar baseline characteristics, except that
the patients allocated to high-dose antivenom had higher
venom concentrations and a statistically significantly
shorter time to antivenom administration (3.1 h
[IQR 2.3–4 h] versus 4.1 h [IQR 2.9–5.5 h]) (Table 1;
Fig. S1). The use of 20WBCT to define coagulopathy
resulted in 11 patients being recruited without coagulopa-
thy being measured by a subsequent retrospective INR
[25]. In addition, six patients with hump-nosed viper
(Hypnale spp.) bites were inadvertently recruited (later
identified by venom analysis), because this snake also
causes coagulopathy and an abnormal 20WBCT [25,26].
Primary outcome
In an intention to treat analysis, 23 of 69 (33%) patients
allocated to the high-dose antivenom group had an INR
of < 2 at 6 h after antivenom administration as compared
with 28 of 67 (42%) allocated to the low-dose antivenom
plus FFP group (absolute difference of 8%;
Total snakebites
2076
Eligible patients with VICC
214
Randomized patients
141
High-dose AV
70
Low-dose AV + FFP
71
Did not consent or clinician
unwilling to recruit
73
Ineligible cases (1862):
-    late identification
-    definitely not Russell’s viper
-    negative 20WBCT
-    antivenom already given
No post-AV samples
1
No post-AV samples*
4
INR > 2 at 6 h
39
INR > 2 at 6 h
46
INR < 2 at 6 h
23
INR < 2 at 6 h
28
Fig. 1. CONSORT diagram showing all snakebite patients present-
ing to both hospitals, the number of eligible patients, patients who
did not consent, and patients for whom no outcome data were avail-
able because no blood was collected after antivenom (AV) adminis-
tration. FFP, fresh frozen plasma; INR, International Normalized
Ratio; VICC, venom-induced consumption coagulopathy; 20WBCT,
20-min whole blood clotting test.
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95% CI  8% to 25%) (Fig. 2). In a per-protocol analy-
sis, which was restricted to 119 patients receiving the allo-
cated treatment, 22 of 65 (34%) given high-dose
antivenom had an INR of < 2 at 6 h after antivenom
administration as compared with 25 of 52 (48%) receiving
low-dose antivenom and FFP (absolute difference of
14%; 95% CI  4% to 32%). This per-protocol analysis
excluded four patients allocated to the high-dose antive-
nom group, who were given FFP within 4 h, and 15
patients allocated to the low-dose antivenom and FFP
group, who were not given FFP (Fig. S2). The median
time to an INR of < 2 after antivenom administration for
patients given high-dose antivenom was 12.9 h, as com-
pared with 12 h (Gehan–Breslow–Wilcoxon test) for
patients given low-dose antivenom and FFP (Fig. 3).
Thirty-four patients of 136 either had an INR of > 2 for
the last blood collection time point (right censored) or an
INR that was never > 2 (excluded).
To assess the best possible effect of FFP, we included
only the 118 patients who developed coagulopathy (INR
of > 2, rather than a positive 20WBCT) and had an INR
measured 4–9 h after antivenom administration. Of these
118, 17 of 72 (24%) given high-dose antivenom had an
INR of < 2 at 6 h, as compared with 21 of 46 (46%) who
actually received low-dose antivenom and FFP (absolute
difference of 22%; 95% CI 5–39%) (Table 2).
Secondary outcomes
Immediate systemic hypersensitivity reactions occurred in
50 of 140 patients in the study given antivenom with or
without FFP, and 30 had severe anaphylaxis. There was
no difference in reaction rates between high-dose antive-
nom and low-dose antivenom with FFP (Table 3).
Administration of FFP was stopped after receipt of one
unit in one patient, owing to the development of clinical
features consistent with TRALI; this patient was then
given further antivenom, and eventually died.
A recurrence of the coagulopathy (INR of > 2) in
patients with an INR of < 2 at 6 h occurred in two of 69
patients allocated to high-dose antivenom, and in two of
67 in patients allocated to low-dose antivenom and FFP.
There were 94 patients in whom Russell’s viper venom
was detected in a pre-antivenom sample. Venom recur-
rence after antivenom administration occurred in nine of
53 (17%) patients allocated to high-dose antivenom, and
in 10 of 41 (24%) patients allocated to low-dose antive-
nom with FFP.
A repeat dose of antivenom was given to 27 of 69
(39%) patients given high-dose antivenom, and to 18 of
67 (27%) patients given low-dose antivenom. Four
patients had a repeat dose within 6 h of antivenom
administration, and all were in the low-dose group. One
patient was the patient who had FFP stopped because of
becoming unwell. Two patients had repeat abnormal
20WBCTs after the first antivenom dose had been com-
pleted (2 h and 3 h after antivenom administration), and
Table 1 Comparison of the demographic features and clinical effects
for patients allocated to high-dose antivenom and those allocated to
low-dose antivenom and fresh frozen plasma (FFP)
High-dose
antivenom
(n = 69) %
Low-dose
antivenom
+ FFP
(n = 67) %
Sex (male) 54 78 52 78
Age (years),
median (IQR)
38 (31–51) 45 (27–54)
Snake type
Russell’s viper 63 91 60 90
Venom
concentration
(ng mL1),
median (IQR)
247 (24–692) 86 (26–312)
Hospital
Polonnaruwa 48 70 47 70
Kurunegala 21 30 20 30
Time to admission (h),
median (IQR)
1.75 (1.1–2.5) 1.9 (1.2–3)
Time to antivenom
administration from
bite, (h), median (IQR)
3.1 (2.3–4) 4.1 (2.9–5.5)*
IQR, interquartile range. *One patient did not have a bite time; this
was significantly different.
8
4
2
16
1
High-dose antivenom
IN
R
 a
t 6
 h
 a
fte
r a
nt
ive
n
o
m
 a
dm
in
ist
ra
tio
n
Low-dose antivenom + FFP
Fig. 2. Scatter plot of the International Normalized Ratio (INR)
measured at 6 h after antivenom administration, comparing those
randomized to high-dose antivenom with those randomized to low-
dose antivenom and fresh frozen plasma (FFP), for the intention to
treat analysis. The shaded area represents an unrecordable INR (in-
coagulable blood).
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a further 10 vials were given. In a fourth patient, a repeat
20WBCT was performed during the infusion of the first
antivenom dose, and was abnormal.
There were a total of three deaths, all in the low-dose
antivenom and FFP group, and all at one hospital. The
first was a 56-year-old female who became acutely unwell
immediately following the commencement of FFP and
developed clinical features of TRALI, as well as acute
kidney injury. She died on day 10. A 46-year-old male
had a left parietal intracranial hemorrhage with extension
into the ventricles and subarachnoid space with mass
effect and uncus herniation. He died on day 3. The third
was a 66-year-old female with diabetes and hypertension
who presented with hematuria and acute renal failure,
developed an ST elevation myocardial infarct on electro-
cardiogram, was positive for troponin I, and had a car-
diac arrest and died 25 h post-bite. There were no other
intracranial hemorrhages or major hemorrhages.
Clotting factor analysis
There were 77 patients who had both detectable Russell’s
viper venom and sufficient timed samples for an analysis
of all clotting factors; 44 received high-dose antivenom
and 33 received low-dose antivenom and 4 U of FFP
within 6 h. The median highest INR and APTT were
> 12 (1.6 to > 12) and 180 s (28–180 s), respectively. The
median lowest fibrinogen, FV, FX and FVIII levels and
the median peak D-dimer level were < 0.2 g L1 (< 0.2
to 1.1 g L1), 2.5% (2.5–45%), 25% (2.5–86%), 97%
(2.5–292%), and 376 mg L1 (4.8–909 mg L1), respec-
tively. There was no significant difference between groups.
There was no significant difference in time to recovery of
INR to 2 or fibrinogen to 1 g L1 (Fig. 4A). There was
statistically significantly more rapid recovery of FV
(Gehan–Breslow–Wilcoxon test; Fig. 4B) and FX
(Fig. 4C) in the low-dose antivenom group within 24 h.
There was no significant difference in the D-dimer AUC
between groups (median 4208 g L1 h versus
3469 g L1 h; Fig. 4D). Visual inspection of plots of
INR, fibrinogen, FV, FVIII, FX and D-dimer versus
time, comparing the two groups, showed little difference
High-dose antivenom
High-dose antivenom
Low-dose antivenom + FFP
Low-dose antivenom + FFP
Time after antivenom administration (h)
24
12
36A
B
0
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2
Fig. 3. Scatter plot of the time until the International Normalized
Ratio (INR) was < 2 (A) and a survival curve of the time to INR of
< 2 (B), comparing patients randomized to high-dose antivenom
(thick line) with patients randomized to low-dose antivenom and
fresh frozen plasma (FFP) (dashed line), for the intention to treat
analysis.
Table 2 Additional primary outcome analyses compared with the Australian randomized controlled trial of fresh frozen plasma (FFP)
Primary outcome
(INR of < 2 at 6 h) N
High
dose % N
Low
dose + FFP % Difference (%) (95% CI)
Intention to treat 69 23 33 67 28 42 8  8 to 25
Per protocol 65 22 34 52 25 48 14  4 to 32
Non-randomized treatment with
FFP excluding first INR
of < 2* + INR at 3–9 h only†
72 17 24 46 21 46 22 5–39
Australian controlled trial of FFP‡ 24 6 25 41 30 73 48 23–73
CI, confidence interval; INR, International Normalized Ratio. *Excluding all cases where the INR was < 2 on admission and remained at < 2.
†For the primary outcome, the closest sample to 6 h after antivenom administration was used for analysis, including all samples; in this analy-
sis, patients were excluded if the sample was taken earlier than 4 h or later than 9 h after antivenom administration. ‡In this study, patients
were randomized to FFP or no FFP and the same antivenom dose.
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in recovery of factors except for FV (Fig. S3). Timed fib-
rinogen, FV and FX data were then globally fitted to a
one-phase association equation for those receiving FFP
versus those not receiving FFP (Fig. S4). The half-time of
recovery of FV for patients receiving FFP was 13.2 h
(95% CI 8.3–38 h), which was shorter than that for those
not receiving FFP, i.e. 24.2 h (95% CI 13–200 h).
Discussion
The study has two important findings. The first is that
the lower dose of 10 vials of antivenom appeared to be as
effective as the higher dose. The second, more interesting,
finding is that, although FFP appeared to more rapidly
improve the coagulopathy in some patients, there was no
significant overall benefit. Our pragmatic study of clinical
effectiveness had the same difficulties in identifying
patients who would benefit from and received FFP, as
would be experienced in non-trial settings; only 77% of
those allocated to the FFP arm actually received it. Thus,
the study demonstrates the lack of general clinical benefit
of attempted routine use of a set dose of FFP in this
resource-poor setting. This is in contrast to what would
be expected to happen (say) with FFP given to an indi-
vidual patient with a clearly documented high INR and
life-threatening bleeding after VICC.
Table 3 Secondary outcomes for patients who received high-dose antivenom compared with those who received low-dose antivenom and fresh
frozen plasma (FFP)
Outcome N
High
dose % N
Low
dose + FFP %
Difference
(%) (95% CI)
Systemic hypersensitivity reaction* 84 28 33 56 22 39 6  10 to 22
Severe anaphylaxis* 84 17 20 56 11 23 3  11 to 17
Recurrence
Venom antigenemia 53 9 17 41 10 24 7%  9 to 24
Hypofibrinogenemia 74 1 1 52 1 2 – –
Repeat antivenom dose (one or more) 69 27 39 67 18 27 15  2 to 32
Major hemorrhage 69 0 67 1 –
Death 69 0 67 3 –
CI, confidence interval. *One patient was not given antivenom.
50
0
100
A B
C D
30
AV
AV + FFP
20100 40
Titme after antivenom administration (h)
Titme after antivenom administration (h)
Titme after antivenom administration (h)
6040200 80
20 400 60
Pe
rc
e
n
ta
ge
 w
ith
 fi
br
in
og
en
 >
1 
g 
L–
1
50
0
100
Pe
rc
e
n
ta
ge
 w
ith
 fa
ct
or
 X
 >
 5
0%
50
0
100
Pe
rc
e
n
ta
ge
 w
ith
 fa
ct
or
 V
 >
 5
0%
30 000
20 000
10 000
0
40 000
AU
C 
(D
-di
me
r)
AV
AV + FFP
AV
AV
 
+ 
FF
P
AV
AV + FFP
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There was a significant but small difference in median
time to antivenom of 1 h, with administration of antive-
nom being delayed in the low-dose antivenom group.
This may have been because organizing a cross-match
and planning administration of FFP slowed the process
of giving antivenom. This increase from a median of 3–
4 h post-bite is potentially clinically significant. Some
studies have shown that the benefit of antivenom is mea-
sured in hours, particularly within the first 6 h post-bite
[27,28].
Administration of FFP can only benefit patients who
have developed coagulopathy. Eleven patients who never
developed coagulopathy were included because they had
a positive 20WBCT. We have previously outlined the
poor sensitivity of the 20WBCT for detecting VICC, but
found a poor specificity in patients recruited to this study
[25]. If a laboratory INR had been used to determine
whether patients had VICC, these patients would have
been excluded. Predictably, we observed a greater effect
of FFP when these patients were excluded from analyses
(Table 2).
The graphs of the time to recovery of fibrinogen, FV
and FX suggest that, in the FFP group, there is more
rapid recovery of these factors in the first 24 h than in
the high-dose antivenom group (Fig. 4); this is only sig-
nificant for FV and FX. However, on further analysis of
serial factor concentrations, only FV had a shorter half-
time of recovery (13.6 h versus 24.2 h; Figs S3 and S4).
After 24 h, the recovery appeared to be similar in both
groups, indicating that FFP provides a transiently more
rapid improvement for some factors. Even when patients
unlikely to benefit from FFP were excluded, and
acknowledging that this was not a prespecified outcome,
the magnitude of the absolute difference in this study
was still only half that seen in the Australian study
(Table 2). Despite the Australian study of FFP in snake-
bite showing a highly significant improvement in coagu-
lopathy, it did not lead to earlier discharge or clinical
benefit [5].
There were three deaths in the low-dose antivenom
group, but only one appeared to be related to FFP treat-
ment, with TRALI developing. However, the diagnosis of
TRALI could not be confirmed, the reaction occurred
immediately after administration of 1 U of FFP, and the
patient developed acute kidney injury related to envenom-
ing. The patient immediately received further doses of
antivenom. The other two patients developed severe com-
plications of envenoming, and also received further anti-
venom doses.
A potential limitation of the study was that it was
underpowered, with only 136 patients being included in
the intention to treat analysis, rather than the 170
patients specified by the sample size calculation. It is pos-
sible that an additional 30 patients may have produced a
positive trial with a very small effect size, but this would
have still not been clinically beneficial.
Another major limitation of the study was the number
of patients randomly allocated to the low-dose antivenom
and FFP group who did not receive FFP. In the majority
of cases, this was attributable to the inability to cross-
match the patient (Fig. S2), although, in some cases, it
was attributable to changing shifts or new doctors refus-
ing to administer the treatment after inclusion in the
study. This reduced the effective power of the study, and
is one potential reason for the negative intention to treat
outcome, despite a favorable trend in patients actually
given FFP. Almost one-third of patients received further
antivenom, but this was given 6 h or more after the initial
dose in all but four cases.
Patients allocated to low-dose antivenom and FFP
received antivenom 1 h later than the high-dose group.
This may have affected the outcome, biasing a successful
outcome to the high-dose group. However, a delay in
antivenom administration of 1 h is unlikely to have a
major effect on FFP administration, and all patients allo-
cated to FFP and who were given FFP received it within
6 h. This study adds further to the evidence base on FFP
in VICC, which is a major complication of many snake-
bites worldwide. In contrast to the Australian study [5],
we found that FFP was only beneficial in a subgroup of
patients who were not easily identified in a resource-poor
setting where 20WBCT is relied on for diagnosis. In addi-
tion, the use of FFP appeared to delay antivenom admin-
stration, and it was sometimes impractical to administer.
Although we were not able to demonstrate that FFP
improved rates of recovery from VICC in this setting, we
saw no evidence that it worsened or prolonged coagu-
lopathy. This is reassuring for its potential role in treating
hemorrhagic complications, and also encourages further
studies with other snake species, such as Echis spp. (saw-
scaled and carpet vipers) [8], Crotalus spp. and Bothrops
spp. (vipers from the Americas) [29], and Calloselasma
rhodostoma (Malaysian pit viper)[30]. As many of these
snakes occur in resource-poor parts of the world, routine
FFP administration is likely to be of limited clinical bene-
fit, so the focus should remain on early administration of
antivenoms.
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Fig. S1. Scatter plot of the time to antivenom comparing
patients given high-dose antivenom to those given low-
dose antivenom with FFP.
Fig. S2. Flow chart showing all allocated patients, the
number included in the intention to treat analysis and
then the patients not given their allocated treatment (ex-
cluded in the per-protocol analysis) and who then chan-
ged arms for the non-randomized analysis because either
FFP was administered when it should not have been, or
was not administered when it should have been.
Fig. S3. Plots of International Normalized Ratio (INR;
A, B), fibrinogen (C, D), factor V (E, F), factor VIII (G,
H) and factor X (I, J) versus time comparing those given
high-dose antivenom (left-sided graphs) versus those
receiving low-dose antivenom and FFP (right-sided
graphs). Note: factor VIII is initially high because of the
artificial effect that Russell’s viper venom has on the fac-
tor VIII assay (see Isbister et al.) [13]
Fig. S4. Predicted time course of factor V (red), factor X
(black) and fibrinogen (blue), comparing FFP (thick line)
to no FFP (dashed line), when the observed data were fit-
ted to a one-phase association model demonstrating the
early increase in factor V in the FFP group.
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